GlassScriptPhysician profile
Anne Marie Chu
NPI 1255323598
$7,873.19
in general payments reported to CMS, 2019-2025
33 companies · $832 in 2025
The $832 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $186 · 2021: $821 · 2022: $1,187 · 2023: $1,924 · 2024: $2,167 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,923.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,737.84 | 2022-2025 | Infuse, Biotrue One Day, Xiidra |
| Alcon Vision LLC | $1,030.48 | 2019-2025 | Clareon, Tryptyr, Argos |
| Sun Pharmaceutical Industries INC. | $880.92 | 2019-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $602.11 | 2021-2025 | Acuvue |
| Abbvie INC. | $392.20 | 2022-2025 | Durysta |
| Novartis Pharmaceuticals Corporation | $392.14 | 2019-2023 | |
| Coopervision INC. | $387.84 | 2019-2025 | Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $378.20 | 2019-2021 | |
| Oyster Point Pharma, INC. | $355.81 | 2022-2025 | Tyrvaya, Ryzumvi |
| Regeneron Healthcare Solutions, INC. | $270.35 | 2023-2025 | Eylea, Eylea Hd |
| Harrow Eye, LLC | $219.61 | 2024-2025 | Vevye |
| Biotissue Holdings INC. | $162.63 | 2024 | |
| Allergan, INC. | $141.94 | 2021-2022 | |
| Quidel Corporation | $110.13 | 2022 | |
| Lkc Technologies, INC. | $98.97 | 2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $98.30 | 2024-2025 | Vabysmo |
| Visioneering Technologies, INC. | $89.68 | 2019-2020 | |
| Horizon Therapeutics Plc | $75.92 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $62.98 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $59.31 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $43.92 | 2025 | Iluvien |
| Alimera Sciences, INC. | $39.39 | 2023-2024 | Yutiq, Iluvien |
| Abb Con-Cise Optical Group LLC | $38.28 | 2019-2024 | Contact Lens, Spectacle Lenses |
| Genentech, INC. | $27.00 | 2023 | Vabysmo |
| Aerie Pharmaceuticals, INC. | $26.96 | 2019-2020 | |
| Thea Pharma INC. | $21.71 | 2023 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $21.19 | 2024 | Tecnis Simplicity |
| Rayner Intraocular Lenses Limited | $21.19 | 2023 | Rayone Spheric, Rayone Emv, Omidria |
| Omeros Corporation | $20.62 | 2019 | |
| Eyevance Pharmaceuticals LLC | $19.44 | 2022 | |
| Ortho-Clinical Diagnostics, INC. | $17.91 | 2024 | Inflammadry |
| Dompe US, INC. | $15.33 | 2022 | |
| Shire North American Group INC | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Marie Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.